Provided by Tiger Fintech (Singapore) Pte. Ltd.

Trevi Therapeutics, Inc.

6.75
+0.46007.31%
Post-market: 6.75-0.0008-0.01%19:52 EDT
Volume:1.92M
Turnover:12.72M
Market Cap:603.22M
PE:-15.21
High:6.78
Open:6.29
Low:6.28
Close:6.29
Loading ...

Company Profile

Company Name:
Trevi Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
27
Office Location:
195 Church Street,16th Floor,New Haven,Connecticut,United States
Zip Code:
06510
Fax:
- -
Introduction:
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Directors

Name
Position
David Meeker
Director and Chairman
Jennifer Good
Director and President and Chief Executive Officer
Michael Heffernan
Lead Independent Director
Anne VanLent
Director
Dominick Colangelo
Director
Edward Mathers
Director
James Cassella
Director

Shareholders

Name
Position
Jennifer Good
Director and President and Chief Executive Officer
Lisa Delfini
Chief Financial Officer
David Clark
Chief Medical Officer
Farrell Simon
Chief Commercial Officer
Thomas Sciascia
Chief Scientific Officer